Will Overton be a heat shield or a conduit for political and ideological influence?

The answer to that question will determine FDA’s future

President Donald Trump could have chosen an FDA Commissioner whose record signaled a desire to return to regulatory independence and mainstream public health policy.

He chose Heidi Overton instead.

That doesn’t necessarily mean FDA will abandon the normalcy that has begun to take hold since Marty Makary’s departure. The White House is taking steps, including moving toward putting permanent directors of CBER and CDER in place, that are intended to keep the agency running smoothly.

But Overton’s deep ties to MAGA and MAHA politics, along with her record on vaccines, abortion, and other contentious health issues, raise a fundamental question: Will she protect FDA and its staff from political pressure, or serve as a conduit for political and ideological demands?

Under acting Commissioner Kyle Diamantas, FDA is showing clear signs of returning to conventional medical product regulation. Career staff have more freedom to do their jobs, creating a palpable sense inside and outside FDA that the agency is moving in the right direction.

Agency staff tell BioCentury Diamantas has abandoned the erratic, top-down decision-making that characterized Makary’s tenure. Recent approvals suggest that the irrational rejection of mRNA technology has been shelved.

The agency is trying to exercise muscles that atrophied under Makary. It is slowly reviving the routine use of advisory committees. The constraint seems to be practical rather than an attempt to avoid transparency and accountability. Many of the administrative staff who organize meetings were swept out in the DOGE purges and haven’t been replaced.

Political interference now appears episodic rather than systemic. Upcoming decisions about bulk compounding of peptides with unknown health and safety profiles, and possibly about the regulation of mifepristone, will be bellwethers.  

Makary’s departure helps explain how Overton may lead FDA.

His ouster could be read as evidence that the White House wants a more traditional FDA. That would be the wrong conclusion.

Makary wasn’t pushed out because politics and ideology intruded on regulatory decisions. He lost the administration’s confidence because he mismanaged the agency, presided over debilitating leadership churn, empowered unqualified officials, and embroiled the White House and HHS in unnecessary conflicts.

Makary might still be Commissioner if he hadn’t given Vinay Prasad, former CBER director, wide latitude to impose idiosyncratic regulatory theories that led FDA to reject medicines important to patients. Advancing policies, some of questionable legality, that HHS had neither vetted nor approved, was another source of tension.

Above all, Makary lost the White House’s confidence because of his relentless self-promotion on social media. 

Overton was picked because she is viewed in the White House as a team player who will not try to outshine Trump or Kennedy. 

Trump’s actions and false statements about vaccines, the CDC’s erratic response to tragic deaths from measles, and HHS’s nonsensical policies on autism and peptides show that the administration’s approach to public health hasn’t changed.

A heat shield or a conduit?

Much has been made of Overton’s resume, especially her limited experience.

She’s 37 and an M.D. with a Ph.D. in clinical investigation, board-certified in preventive medicine, and has trained in general surgery at Johns Hopkins. At Hopkins she co-authored papers with Makary on opioid overprescribing.

During the first Trump administration, Overton was a White House Fellow. Then she was Chief Policy Officer at the America First Policy Institute, a think tank created to develop and promote Trump’s policy agenda. She returned to the White House in 2025 as Deputy Director of the Domestic Policy Council, where she has helped coordinate the administration’s health agenda.

Precedent shows that being young, lacking FDA experience and having close White House ties need not disqualify someone from successfully leading FDA.

Mark McClellan was 39 when he was nominated as FDA Commissioner. He came to the agency directly from the White House, where he served on the Council of Economic Advisers and as a senior health policy adviser. Unlike Overton, he brought substantial government experience and bipartisan credentials, including service in the Clinton Treasury Department, as well as an extraordinary academic record as an economist, researcher, and practicing physician.

At FDA, McClellan avoided even the appearance of political influence. He was a transformative Commissioner.

The central concern about Overton is not her resume or whether she approaches the stature and expertise of previous commissioners. It is how she will define the job.

Will she, like McClellan and the commissioners who followed him before Makary, act as a heat shield protecting agency scientists from political pressure? 

FDA staff and biopharma leaders are concerned that Overton will see her mission as implementing ideological directives from the White House and HHS Secretary Robert F. Kennedy Jr.

Overton’s questioning of the premise that scientific institutions should be politically neutral adds to those worries. In 2023, she called for “conservative-based” academic journals and research funding designed to generate evidence supporting questions and priorities she believed mainstream institutions neglected. 

She has expressed strong opinions about controversial issues that she would be responsible for at FDA, including opposition to the Biden administration’s relaxation of in-person dispensing requirements for mifepristone, as well as calling for restrictions on access to abortion. 

Overton’s intellectual approach echoes that of Makary, her mentor at Hopkins. Both assert that public health decisions often reflect institutional inertia, professional-society orthodoxy, and corporate capture of the agencies.

Kept within appropriate boundaries, this kind of skepticism is healthy. Hitched to an ideological agenda, it can be toxic.

Asking for evidence that dropping the in-person dispensing requirement for mifepristone is justified is one thing. Starting from the premise that it must be overturned and cherry-picking evidence to justify dropping it would be another.

The Prasad experience shows what can happen when an extreme anti-institutional framework is applied to routine regulatory decisions. He claimed that much of what his predecessors had done reflected industry capture or institutional inertia, and that he was uniquely qualified to ascertain the truth. By disregarding precedent and overturning decisions he disagreed with, Prasad upended drug regulation, creating chaos that FDA has spent months trying to clean up.

Overton hasn’t exhibited the egotism that felled Makary or the arrogance that made Prasad’s tenure disastrous. 

She has demonstrated a willingness to toe the line, including on policies that will reduce access to lifesaving vaccines. She played a central role in Trump’s Aug. 10 “Gold Standard Childhood Vaccine Recommendations” executive order, which narrowed recommendations for childhood vaccines and called for MMR to be split into three single-disease shots.

Overton hasn’t shied away from partisan framing of public health issues that FDA commissioners have traditional avoided. At the White House rollout, Overton criticized “blue states” for following recommendations from groups such as the American Academy of Pediatrics. Mainstream medical organizations have condemned the administration’s new vaccine policies.

Sen. Bill Cassidy (R-La.), Chair of the Health, Education, Labor and Pensions Committee, which has jurisdiction over FDA, criticized Overton. He said her “active role” in the administration’s “nonsensical vaccine executive order calls into question her commitment to standing up for sound science and protecting children’s health.” Cassidy added: “That alone is almost disqualifying.”

Cassidy hasn’t indicated whether he will try to block Overton’s confirmation. Having lost his Republican primary, he will leave the Senate next year, giving the White House an incentive to delay a confirmation vote until the next Congress.

Overton has also come under fire from the MAHA community, especially for her association with a February executive order designating glyphosate production as critical to national defense. MAHA wants the herbicide banned.

The vaccine and glyphosate issues illustrate the costs of politicizing FDA. If public health leaders loosen their moorings from nonpartisan science, they will be whipsawed by competing political constituencies.

Biopharma executives shouldn’t assume Overton’s views on abortion drugs and support for restricting access to vaccines are irrelevant to the products they develop in other therapeutic areas. That is the kind of compartmentalized thinking that led most CEOs to remain silent when Kennedy was nominated and when Makary and Prasad politicized regulation. The concern isn’t her opinions, it is whether she would ground her actions at FDA in science and the law. 

The industry cannot separate its commercial interests from the integrity of the public health system.

If confirmed, Overton will have a choice. She can resist attempts to inject politics and personal influence into FDA decisions and accelerate the agency’s recovery from the DOGE and Makary. Or she can reverse that recovery. The consequences will extend beyond FDA to patients, public health, and the industries the agency regulates.

Signed commentaries do not necessarily reflect the views of BioCentury.